Related Experiment Video

Updated: Jun 3, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors

Jonathan Trent1, Mathieu Molimard

  • 1Department of Sarcoma Medical Oncology and The Adult Sarcoma Research Center, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jtrent@mdanderson.org

Seminars in Oncology
|March 23, 2011
PubMed

Insights

Nilotinib, a tyrosine kinase inhibitor, shows favorable pharmacokinetics for treating GIST and CML. It is well-tolerated and effective in imatinib-resistant GIST patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Nilotinib is a targeted therapy drug.
  • It inhibits specific tyrosine kinases implicated in cancer growth.

Purpose of the Study:

  • To evaluate the pharmacokinetics and safety of nilotinib.
  • To assess its efficacy in imatinib-resistant gastrointestinal stromal tumors (GIST).

Main Methods:

  • Pharmacokinetic studies in healthy volunteers and patients.
  • Clinical trials involving patients with chronic myelogenous leukemia (CML) and GIST.

Main Results:

  • Nilotinib exhibits pharmacokinetics similar to imatinib, supporting twice-daily dosing.
  • Maximum plasma concentration is reached in 3-4 hours, with a 17-hour half-life.
  • Preliminary data suggest clinical benefit and safety in imatinib-resistant GIST.

Conclusions:

  • Nilotinib demonstrates suitable pharmacokinetics for therapeutic use.
  • The drug shows promise for treating imatinib-resistant GIST.
  • Nilotinib is a potential therapeutic option in oncology.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...